Skip to main content

Measurements of RV on Echocardiography




Major Echocardiographic Views and Normal Dimensions of the Right Ventricle (RV) and Right Atrium (RA)


Right heart assessment is essential in pulmonary hypertension, congenital heart disease, RV infarction, cardiomyopathy, and advanced left-sided heart disease. Accurate chamber quantification should follow the recommendations of the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI).


Right heart measurements are ideally obtained at end-diastole (for RV size) and end-systole (for RA area), using RV-focused views whenever possible.


━━━━━━━━━━━━━━━━━━


1. Apical 4-Chamber View (RV-Focused View)


This is the most important view for quantitative RV and RA assessment.


Technique: • Optimize by centering and enlarging the RV

• Avoid LV foreshortening

• Measure RV at end-diastole

• Measure RA at end-systole


Right Ventricle – Normal Dimensions (End-Diastole)


• RV Basal Diameter (RVD1): 25–41 mm

• RV Mid Cavity Diameter (RVD2): 19–35 mm

• RV Longitudinal Length (RVD3): 59–83 mm


RV Enlargement: • Basal diameter > 41 mm

• RV/LV basal ratio > 1


Right Atrium – Normal Dimensions (End-Systole)


• RA Major Dimension: ≤ 53 mm

• RA Minor Dimension: ≤ 44 mm

• RA Area: ≤ 18 cm²


RA Enlargement: • RA area > 18 cm²


Clinical relevance: RA enlargement correlates with chronic pressure overload, pulmonary hypertension, and adverse prognosis.


━━━━━━━━━━━━━━━━━━


2. Parasternal Long Axis (RV Inflow View)


Used for: • Tricuspid valve morphology

• RV inflow tract

• RV free wall thickness


RV Wall Thickness


Measured in subcostal view (preferred) or PLAX at end-diastole.


Normal: • ≤ 5 mm


RV Hypertrophy: • > 5 mm (suggests chronic pressure overload e.g., pulmonary hypertension)


━━━━━━━━━━━━━━━━━━


3. Parasternal Short Axis View


Provides complementary assessment.


Mid-ventricular level: • Compare RV size to LV

• Assess septal flattening


Septal flattening: • Systolic flattening → Pressure overload

• Diastolic flattening → Volume overload

• Persistent D-shaped LV → Severe pulmonary hypertension


RVOT Measurements


Measured in PLAX and PSAX.


Normal Values: • Proximal RVOT (PLAX): 20–30 mm

• Distal RVOT (PSAX): 17–27 mm


Enlargement suggests pulmonary hypertension or congenital heart disease.


━━━━━━━━━━━━━━━━━━


4. Subcostal View


Best for: • RV free wall thickness

• RA size

• IVC assessment


Although not a primary view for chamber quantification, it is particularly useful in patients with poor parasternal windows.


━━━━━━━━━━━━━━━━━━


Practical Approach to Right Heart Size Assessment


Step 1: Start with RV-focused apical 4-chamber

Step 2: Measure RVD1, RVD2, RVD3

Step 3: Measure RA area at end-systole

Step 4: Assess RV/LV ratio

Step 5: Confirm with parasternal and subcostal views

Step 6: Integrate with functional parameters (TAPSE, S′, FAC)


Right ventricular size alone is insufficient; always interpret in clinical context.


━━━━━━━━━━━━━━━━━━


Key Reporting Cutoffs (Quick Reference)


RV Dilatation: • RVD1 > 41 mm

• RV/LV basal ratio > 1


RA Dilatation: • RA area > 18 cm²


RV Hypertrophy: • Wall thickness > 5 mm


━━━━━━━━━━━━━━━━━━


Important Clinical Correlations


RV Dilatation Causes: • Pulmonary hypertension

• Pulmonary embolism

• Severe TR

• Congenital shunts

• RV cardiomyopathy


RA Enlargement Causes: • Chronic pulmonary hypertension

• Long-standing TR

• Atrial arrhythmias

• Right-sided volume overload


━━━━━━━━━━━━━━━━━━


Final Take-Home Points


• Use RV-focused apical 4-chamber for accurate measurement

• Measure RV at end-diastole, RA at end-systole

• RV basal diameter > 41 mm indicates enlargement

• RA area > 18 cm² indicates enlargement

• Wall thickness > 5 mm suggests RV hypertrophy

• Always interpret size with RV function and clinical scenario


Accurate right heart quantification improves diagnostic precision and prognostic stratification in cardiology practice.


Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.